This HTML5 document contains 152 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n8http://www.rxlist.com/cgi/generic4/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00351/identifier/chebi/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00351/identifier/wikipedia/
n12http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00351/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00351/identifier/kegg-compound/
n5http://linked.opendata.cz/resource/drugbank/patent/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n27http://www.drugs.com/cdi/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00351/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/property/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00351/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00351/identifier/national-drug-code-directory/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00351
rdf:type
n3:Drug
n3:description
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer. [PubChem]
n3:dosage
n4:271B5DD1-363D-11E5-9242-09173F13E4C5 n4:271B5DD2-363D-11E5-9242-09173F13E4C5 n4:271B5DD3-363D-11E5-9242-09173F13E4C5 n4:271B5DCD-363D-11E5-9242-09173F13E4C5 n4:271B5DCE-363D-11E5-9242-09173F13E4C5 n4:271B5DCF-363D-11E5-9242-09173F13E4C5 n4:271B5DD0-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Berenstein EG, Ortiz Z: Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004310. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15846706 # Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, Herdman M: Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage. 2004 Apr;27(4):360-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15050664 # Rao GG, Miller DS: Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther. 2006 Jan;6(1):43-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16375643 # Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH: Classification and pharmacology of progestins. Maturitas. 2008 Sep-Oct;61(1-2):171-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19434889 # Orme LM, Bond JD, Humphrey MS, Zacharin MR, Downie PA, Jamsen KM, Mitchell SL, Robinson JM, Grapsas NA, Ashley DM: Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression. Cancer. 2003 Jul 15;98(2):397-405. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12872362
n3:group
approved
n3:halfLife
34 hours
n3:indication
For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.
n3:manufacturer
n11:271B5DC1-363D-11E5-9242-09173F13E4C5 n11:271B5DC2-363D-11E5-9242-09173F13E4C5 n11:271B5DBF-363D-11E5-9242-09173F13E4C5 n11:271B5DC0-363D-11E5-9242-09173F13E4C5 n11:271B5DBD-363D-11E5-9242-09173F13E4C5 n11:271B5DBE-363D-11E5-9242-09173F13E4C5 n11:271B5DBC-363D-11E5-9242-09173F13E4C5 n11:271B5DC3-363D-11E5-9242-09173F13E4C5 n11:271B5DC4-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00351 n12:DB00351
dcterms:title
Megestrol acetate
adms:identifier
n17:DB00351 n18:C08151 n19:D00952 n20:6723 n21:0054-3542-58 n22:PA450351 n23:Megestrol
n3:mechanismOfAction
The precise mechanism by which megestrol acetate produces effects in anorexia and cachexia is unknown at the present time, but its progestin antitumour activity may involve suppression of luteinizing hormone by inhibition of pituitary function. Studies also suggest that the megestrol's weight gain effect is related to its appetite-stimulant or metabolic effects rather than its glucocorticoid-like effects or the production of edema. It has also been suggested that megestrol may alter metabolic pathyways via interferences with the production or action of mediators such as cachectin, a hormone that inhibits adipocyte lipogenic enzymes.
n3:packager
n11:271B5DBB-363D-11E5-9242-09173F13E4C5 n11:271B5DB5-363D-11E5-9242-09173F13E4C5 n11:271B5DB6-363D-11E5-9242-09173F13E4C5 n11:271B5DB3-363D-11E5-9242-09173F13E4C5 n11:271B5DB4-363D-11E5-9242-09173F13E4C5 n11:271B5DB9-363D-11E5-9242-09173F13E4C5 n11:271B5DBA-363D-11E5-9242-09173F13E4C5 n11:271B5DB7-363D-11E5-9242-09173F13E4C5 n11:271B5DB8-363D-11E5-9242-09173F13E4C5 n11:271B5DAD-363D-11E5-9242-09173F13E4C5 n11:271B5DAE-363D-11E5-9242-09173F13E4C5 n11:271B5DAB-363D-11E5-9242-09173F13E4C5 n11:271B5DAC-363D-11E5-9242-09173F13E4C5 n11:271B5DB1-363D-11E5-9242-09173F13E4C5 n11:271B5DB2-363D-11E5-9242-09173F13E4C5 n11:271B5DAF-363D-11E5-9242-09173F13E4C5 n11:271B5DB0-363D-11E5-9242-09173F13E4C5 n11:271B5DA5-363D-11E5-9242-09173F13E4C5 n11:271B5DA6-363D-11E5-9242-09173F13E4C5 n11:271B5DA3-363D-11E5-9242-09173F13E4C5 n11:271B5DA4-363D-11E5-9242-09173F13E4C5 n11:271B5DA9-363D-11E5-9242-09173F13E4C5 n11:271B5DAA-363D-11E5-9242-09173F13E4C5 n11:271B5DA7-363D-11E5-9242-09173F13E4C5 n11:271B5DA8-363D-11E5-9242-09173F13E4C5 n11:271B5D9D-363D-11E5-9242-09173F13E4C5 n11:271B5D9E-363D-11E5-9242-09173F13E4C5 n11:271B5D9B-363D-11E5-9242-09173F13E4C5 n11:271B5D9C-363D-11E5-9242-09173F13E4C5 n11:271B5DA1-363D-11E5-9242-09173F13E4C5 n11:271B5DA2-363D-11E5-9242-09173F13E4C5 n11:271B5D9F-363D-11E5-9242-09173F13E4C5 n11:271B5DA0-363D-11E5-9242-09173F13E4C5 n11:271B5D96-363D-11E5-9242-09173F13E4C5 n11:271B5D99-363D-11E5-9242-09173F13E4C5 n11:271B5D9A-363D-11E5-9242-09173F13E4C5 n11:271B5D97-363D-11E5-9242-09173F13E4C5 n11:271B5D98-363D-11E5-9242-09173F13E4C5
n3:patent
n5:5145684 n5:7101576
n3:routeOfElimination
The major route of drug elimination in humans is urine. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces.
n3:synonym
Volidan 6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone Magestin 17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate Niagestin 6-Methyl-17α-acetoxypregna-4,6-diene-3,20-dione Megestat Megeron 6-Methyl-delta(sup 6)-dehydro-17α-acetoxyprogesterone 6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione Ovaban Maygace 6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate 17alpha-Acetoxy-6-dehydro-6-methylprogesterone Megestin 6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate Ovarid Megestil 6-Methyl-17α-hydroxy-delta(sup 6)-progesterone acetate 6-Methyl-6-dehydro-17alpha-acetoxyprogesterone Megace 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione 6-Methyl-6-dehydro-17α-acetoxyprogesterone 6-Dehydro-6-methyl-17α-acetoxyprogesterone 17α-Acetoxy-6-dehydro-6-methylprogesterone 6-Methyl-delta(sup 4,6)-pregnadien-17α-ol-3,20-dione acetate 6-Dehydro-6-methyl-17alpha-acetoxyprogesterone 17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate MGA 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate
n3:toxicity
No serious unexpected side effects have resulted from studies involving megestrol acetate oral suspension administered in dosages as high as 1200 mg/day. Treatment with megestrol acetate, an orexigenic agent, has also resulted in iatrogenic adrenal suppression. The mechanism is presumably related to the glucocorticoid properties of megestrol acetate [PMID: 12872362].
n13:hasAHFSCode
n14:10-00-00
n3:foodInteraction
Take with food.
n3:synthesisReference
Klaus ANNEN, Thomas Linz, Karl-Heinz Neff, Rolf Bohlmann, Henry Laurent, "PROCESS FOR PREPARING 17ALPHA-ACETOXY-6-METHYLENEPREGN-4-ENE-3,20-DIONE, MEDROXYPROGESTERONE ACETATE AND MEGESTROL ACETATE." U.S. Patent US20090012321, issued January 08, 2009.
n24:hasConcept
n25:M0013296
foaf:page
n8:megace_es.htm n27:megestrol.html
n3:IUPAC-Name
n6:271B5DD8-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B5DDE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B5DDD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B5DDA-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B5DDB-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B5DDC-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B5DD6-363D-11E5-9242-09173F13E4C5 n6:271B5DEE-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B5DD4-363D-11E5-9242-09173F13E4C5 n6:271B5DD7-363D-11E5-9242-09173F13E4C5 n6:271B5DF0-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B5DD5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n6:271B5DE4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B5DE5-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B5DDF-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B5DE0-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B5DE2-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B5DE1-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B5DE3-363D-11E5-9242-09173F13E4C5
n3:absorption
Variable, but well absorbed orally.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
595-33-5
n3:category
n3:containedIn
n15:271B5DC9-363D-11E5-9242-09173F13E4C5 n15:271B5DCA-363D-11E5-9242-09173F13E4C5 n15:271B5DC7-363D-11E5-9242-09173F13E4C5 n15:271B5DC8-363D-11E5-9242-09173F13E4C5 n15:271B5DCB-363D-11E5-9242-09173F13E4C5 n15:271B5DCC-363D-11E5-9242-09173F13E4C5 n15:271B5DC5-363D-11E5-9242-09173F13E4C5 n15:271B5DC6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B5DEA-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B5DEC-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B5DED-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B5DEF-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B5DE9-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B5DE8-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B5DEB-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B5DD9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B5DE6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B5DE7-363D-11E5-9242-09173F13E4C5